Syncona Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SYNC.L research report →
Companywww.synconaltd.com
Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules.
- CEO
- Christopher J. Hollowood
- IPO
- 2012
- Employees
- 1,050
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $588.73M
- P/E
- -6.30
- P/S
- 9.15
- P/B
- 0.58
- EV/EBITDA
- -7.88
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 31.08%
- Op Margin
- -116.07%
- Net Margin
- -145.42%
- ROE
- -9.02%
- ROIC
- -7.28%
Growth & Income
- Revenue
- $-68,312,000 · -322.16%
- Net Income
- $-143,160,000 · -3879.30%
- EPS
- $-0.23 · -4065.52%
- Op Income
- $-143,160,000
- FCF YoY
- -100.00%
Performance & Tape
- 52W High
- $102.60
- 52W Low
- $79.60
- 50D MA
- $90.65
- 200D MA
- $95.70
- Beta
- 0.31
- Avg Volume
- 643.71K
Get TickerSpark's AI analysis on SYNC.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SYNC.L Coverage
We haven't published any research on SYNC.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SYNC.L Report →